



Iodine I-125

Revised: January 18, 2021.

CASRN: 14158-31-7

Drug Levels and Effects

Summary of Use during Lactation

Iodine I-125 is implanted temporarily in a sealed container (plaque) to treat localized tumors. During the time that the plaque is in place, the mother and infant must be separated to avoid radiation exposure to the infant. The mother's milk is not affected, and it can be pumped and fed to the infant at a later time.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

A mother nursing an 11-month-old infant was treated with an iodine I-125 plaque for uveal melanoma. The plaque was in place for 2 days during which time she was separated from her infant, but pumped milk for later use. Breastfeeding was resumed after plaque removal.[1]

References

1. Rieth E, Barnett K, Simon J. Perioperative management of a lactating cancer patient undergoing surgical placement and removal of an iodine-125 brachytherapy plaque for uveal melanoma. *Breastfeed Med.* 2020;15:A3–A4. doi: [10.1089/bfm.2020.29162.abstracts](https://doi.org/10.1089/bfm.2020.29162.abstracts).

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Substance Identification

Substance Name

Iodine I-125

CAS Registry Number

14158-31-7

Drug Class

Breast Feeding

Lactation

Brachytherapy

Iodine Radioisotopes

Radiopharmaceuticals